AnHeart Therapeutics of Hangzhou raised $14.6 million in a Series A round from Decheng Capital, a China life science investor. AnHeart uses its expertise in global clinical development to develop innovative products, which it partners at near-term value inflection points. In late 2018, AnHeart in-licensed global rights to an oral, highly selective ROS1/NTRK small molecule inhibitor from Daiichi Sankyo. AB-106 is in two Phase I clinical trials in the US and Japan. After the Phase I trial, AnHeart will assume responsibility for further clinical development.
Source: China Biotoday
